Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P499 | DOI: 10.1530/endoabs.56.P499

Virgen Macarena University Hospital, Seville, Spain.

Objectives: Obesity and type 2 diabetes mellitus (DM2) are risk factors for non-alcoholic fatty liver disease (NAFLD). The main objective was to study the incidence of NAFLD using the Hepatic Steatosis Index (HSI) in obese patients with DM2. Secondary objectives were to analyse the effect of liraglutide over HSI, body mass index (BMI) and glycated hemoglobin (HbA1c).

Methods: Retrospective observational study of obese type 2 diabetic patients treated with liraglutide during the period 2009-2015. Diagnosis of NAFLD was based on the HSI formula=8×(ALT/AST ratio) + BMI (+2, if female; +2, if diabetic).

Results: Study sample of 53 patients, 55% males and 45% females, with a mean age of 49.6 years. 100% of patients presented a positive HSI, which improved in 73.5% of them after treatment with liraglutide. Mean HSI after treatment was significantly lower compared to the previous value (p=0.008). Mean BMI and HbA1c after liraglutide implementation were also significantly lower than before treatment (P=6.004−06 and P=1.074−08, respectively). Triglyceride levels decreased in 60% of patients without statistical significance (P=0.054).

Conclusions: After 3 months of treatment with liraglutide, there was an improvement in HSI, BMI and HbA1c, as well as a reduction in triglyceride levels.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts